Schilke Tobin bought CRNX
August 20, 2026 · Form 4 insider transaction
Schilke Tobin bought 471 shares of Crinetics Pharmaceuticals Inc at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
471
Price
$0.00
Total value
N/A
InsiderSchilke Tobin
Role—
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateAugust 20, 2026
Filing dateAugust 24, 2026
Shares owned after79,427
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027.; Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.